Pasi A. Jänne, MD, PhD, on NSCLC, Osimertinib, Chemotherapy: Update From FLAURA2

May 01, 2024 By The ASCO Post Staff

Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, discusses an exploratory analysis from the FLAURA2 study, which indicates that baseline levels of plasma EGFR mutation may be prognostic and predictive of clinical benefit with osimertinib plus chemotherapy vs osimertinib alone for patients with non–small cell lung cancer (NSCLC).

Related Content